Both Elegen and GSK signed a multi-year collaboration and license agreement that allows GSK to leverage Elegen’s proprietary cell-free DNA manufacturing technology for the development of vaccines & medicines
As per the terms of the agreement, Elegen will receive an up front payment (undisclosed) for its ENFINIA DNA technology and is also eligible to receive an aggregate of $35M in near-term milestone payments for the development of new products along with a potential equity investment by GSK
Elegen’s cell-free synthetic ENFINIA DNA production technology delivers linear DNA up to 7kb in 7 business days that are produced cell-free. The technology was commercially launched by Elegen in Mar 2023
Ref: Elegen | Image: Elegen
Related News:- GSK’s Nucala (mepolizumab) Receives the China’s NMPA Approval for Severe Eosinophilic Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
